12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Idelalisib: Additional Phase I data

Data from 24 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who were continuing treatment in an extension study of an open-label, U.S. Phase I trial showed that twice-daily 150 mg oral idelalisib plus rituximab and/or bendamustine led to 2-year progression-free survival (PFS) and overall survival (OS) rates of 62% and 85%, respectively. The overall response rate (ORR) was 81%, including 1 complete response. Median time to response was 1.9 months. Additionally, data from 22 patients with relapsed or refractory...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >